Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p
The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesen...
Saved in:
Published in | Molecular cancer Vol. 16; no. 1; pp. 118 - 14 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
11.07.2017
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesenchymal transition (EMT) has not been characterized.
Cell proliferation was assessed using CCK-8 and EdU assays, and cell migration and invasion were assessed using scratch assays and transwell invasion assays. Epithelial mesenchymal transition was examined using western blot, qRT-PCR and immunofluorescence staining. Interaction between miRNA and linc00673 was determined using luciferase reporter assays. In vivo experiments were performed to assess tumor formation. In addition, the expression data of NSCLC specimens of TCGA and patient survival data were utilized to explore the prognostic significance of linc00673.
In the present study, we found high linc00673 expression was associated with poor prognosis of NSCLC patients. In vitro experiments showed linc00673 knockdown reversed TGF-β induced EMT, and miR-150-5p was predicted to target linc00673 through bioinformatics tools. Overexpression of miR-150-5p suppressed lin00673's expression while inhibition of miR-150-5p led to significant upregulation of lin00673, suggesting that linc00673 could be negatively regulated by miR-150-5p, which was further confirmed by the inverse correlation between linc00673 and miR-150-5p in NSCLC patients' specimen. Furthermore, we proved that miR-150-5p could directly target linc00673 through luciferase assay, so linc00673 could sponge miR-150-5p and modulate the expression of a key EMT regulator ZEB1 indirectly. In addition, miR-150-5p inhibition abrogated linc00673 silence mediated proliferation, migration, invasion and EMT suppressing effect. Moreover, the inhibition of linc00673 significantly attenuated the tumorigenesis ability of A549 cells in vivo.
We validated linc00673 as a novel oncogenic lncRNA and demonstrated the molecular mechanism by which it promotes NSCLC, which will advance our understanding of its clinical significance. |
---|---|
AbstractList | Background The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesenchymal transition (EMT) has not been characterized. Methods Cell proliferation was assessed using CCK-8 and EdU assays, and cell migration and invasion were assessed using scratch assays and transwell invasion assays. Epithelial mesenchymal transition was examined using western blot, qRT-PCR and immunofluorescence staining. Interaction between miRNA and linc00673 was determined using luciferase reporter assays. In vivo experiments were performed to assess tumor formation. In addition, the expression data of NSCLC specimens of TCGA and patient survival data were utilized to explore the prognostic significance of linc00673. Results In the present study, we found high linc00673 expression was associated with poor prognosis of NSCLC patients. In vitro experiments showed linc00673 knockdown reversed TGF-β induced EMT, and miR-150-5p was predicted to target linc00673 through bioinformatics tools. Overexpression of miR-150-5p suppressed lin00673’s expression while inhibition of miR-150-5p led to significant upregulation of lin00673, suggesting that linc00673 could be negatively regulated by miR-150-5p, which was further confirmed by the inverse correlation between linc00673 and miR-150-5p in NSCLC patients’ specimen. Furthermore, we proved that miR-150-5p could directly target linc00673 through luciferase assay, so linc00673 could sponge miR-150-5p and modulate the expression of a key EMT regulator ZEB1 indirectly. In addition, miR-150-5p inhibition abrogated linc00673 silence mediated proliferation, migration, invasion and EMT suppressing effect. Moreover, the inhibition of linc00673 significantly attenuated the tumorigenesis ability of A549 cells in vivo. Conclusions We validated linc00673 as a novel oncogenic lncRNA and demonstrated the molecular mechanism by which it promotes NSCLC, which will advance our understanding of its clinical significance. The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesenchymal transition (EMT) has not been characterized. Cell proliferation was assessed using CCK-8 and EdU assays, and cell migration and invasion were assessed using scratch assays and transwell invasion assays. Epithelial mesenchymal transition was examined using western blot, qRT-PCR and immunofluorescence staining. Interaction between miRNA and linc00673 was determined using luciferase reporter assays. In vivo experiments were performed to assess tumor formation. In addition, the expression data of NSCLC specimens of TCGA and patient survival data were utilized to explore the prognostic significance of linc00673. In the present study, we found high linc00673 expression was associated with poor prognosis of NSCLC patients. In vitro experiments showed linc00673 knockdown reversed TGF-β induced EMT, and miR-150-5p was predicted to target linc00673 through bioinformatics tools. Overexpression of miR-150-5p suppressed lin00673's expression while inhibition of miR-150-5p led to significant upregulation of lin00673, suggesting that linc00673 could be negatively regulated by miR-150-5p, which was further confirmed by the inverse correlation between linc00673 and miR-150-5p in NSCLC patients' specimen. Furthermore, we proved that miR-150-5p could directly target linc00673 through luciferase assay, so linc00673 could sponge miR-150-5p and modulate the expression of a key EMT regulator ZEB1 indirectly. In addition, miR-150-5p inhibition abrogated linc00673 silence mediated proliferation, migration, invasion and EMT suppressing effect. Moreover, the inhibition of linc00673 significantly attenuated the tumorigenesis ability of A549 cells in vivo. We validated linc00673 as a novel oncogenic lncRNA and demonstrated the molecular mechanism by which it promotes NSCLC, which will advance our understanding of its clinical significance. The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesenchymal transition (EMT) has not been characterized.BACKGROUNDThe function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesenchymal transition (EMT) has not been characterized.Cell proliferation was assessed using CCK-8 and EdU assays, and cell migration and invasion were assessed using scratch assays and transwell invasion assays. Epithelial mesenchymal transition was examined using western blot, qRT-PCR and immunofluorescence staining. Interaction between miRNA and linc00673 was determined using luciferase reporter assays. In vivo experiments were performed to assess tumor formation. In addition, the expression data of NSCLC specimens of TCGA and patient survival data were utilized to explore the prognostic significance of linc00673.METHODSCell proliferation was assessed using CCK-8 and EdU assays, and cell migration and invasion were assessed using scratch assays and transwell invasion assays. Epithelial mesenchymal transition was examined using western blot, qRT-PCR and immunofluorescence staining. Interaction between miRNA and linc00673 was determined using luciferase reporter assays. In vivo experiments were performed to assess tumor formation. In addition, the expression data of NSCLC specimens of TCGA and patient survival data were utilized to explore the prognostic significance of linc00673.In the present study, we found high linc00673 expression was associated with poor prognosis of NSCLC patients. In vitro experiments showed linc00673 knockdown reversed TGF-β induced EMT, and miR-150-5p was predicted to target linc00673 through bioinformatics tools. Overexpression of miR-150-5p suppressed lin00673's expression while inhibition of miR-150-5p led to significant upregulation of lin00673, suggesting that linc00673 could be negatively regulated by miR-150-5p, which was further confirmed by the inverse correlation between linc00673 and miR-150-5p in NSCLC patients' specimen. Furthermore, we proved that miR-150-5p could directly target linc00673 through luciferase assay, so linc00673 could sponge miR-150-5p and modulate the expression of a key EMT regulator ZEB1 indirectly. In addition, miR-150-5p inhibition abrogated linc00673 silence mediated proliferation, migration, invasion and EMT suppressing effect. Moreover, the inhibition of linc00673 significantly attenuated the tumorigenesis ability of A549 cells in vivo.RESULTSIn the present study, we found high linc00673 expression was associated with poor prognosis of NSCLC patients. In vitro experiments showed linc00673 knockdown reversed TGF-β induced EMT, and miR-150-5p was predicted to target linc00673 through bioinformatics tools. Overexpression of miR-150-5p suppressed lin00673's expression while inhibition of miR-150-5p led to significant upregulation of lin00673, suggesting that linc00673 could be negatively regulated by miR-150-5p, which was further confirmed by the inverse correlation between linc00673 and miR-150-5p in NSCLC patients' specimen. Furthermore, we proved that miR-150-5p could directly target linc00673 through luciferase assay, so linc00673 could sponge miR-150-5p and modulate the expression of a key EMT regulator ZEB1 indirectly. In addition, miR-150-5p inhibition abrogated linc00673 silence mediated proliferation, migration, invasion and EMT suppressing effect. Moreover, the inhibition of linc00673 significantly attenuated the tumorigenesis ability of A549 cells in vivo.We validated linc00673 as a novel oncogenic lncRNA and demonstrated the molecular mechanism by which it promotes NSCLC, which will advance our understanding of its clinical significance.CONCLUSIONSWe validated linc00673 as a novel oncogenic lncRNA and demonstrated the molecular mechanism by which it promotes NSCLC, which will advance our understanding of its clinical significance. Abstract Background The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesenchymal transition (EMT) has not been characterized. Methods Cell proliferation was assessed using CCK-8 and EdU assays, and cell migration and invasion were assessed using scratch assays and transwell invasion assays. Epithelial mesenchymal transition was examined using western blot, qRT-PCR and immunofluorescence staining. Interaction between miRNA and linc00673 was determined using luciferase reporter assays. In vivo experiments were performed to assess tumor formation. In addition, the expression data of NSCLC specimens of TCGA and patient survival data were utilized to explore the prognostic significance of linc00673. Results In the present study, we found high linc00673 expression was associated with poor prognosis of NSCLC patients. In vitro experiments showed linc00673 knockdown reversed TGF-β induced EMT, and miR-150-5p was predicted to target linc00673 through bioinformatics tools. Overexpression of miR-150-5p suppressed lin00673’s expression while inhibition of miR-150-5p led to significant upregulation of lin00673, suggesting that linc00673 could be negatively regulated by miR-150-5p, which was further confirmed by the inverse correlation between linc00673 and miR-150-5p in NSCLC patients’ specimen. Furthermore, we proved that miR-150-5p could directly target linc00673 through luciferase assay, so linc00673 could sponge miR-150-5p and modulate the expression of a key EMT regulator ZEB1 indirectly. In addition, miR-150-5p inhibition abrogated linc00673 silence mediated proliferation, migration, invasion and EMT suppressing effect. Moreover, the inhibition of linc00673 significantly attenuated the tumorigenesis ability of A549 cells in vivo. Conclusions We validated linc00673 as a novel oncogenic lncRNA and demonstrated the molecular mechanism by which it promotes NSCLC, which will advance our understanding of its clinical significance. |
ArticleNumber | 118 |
Audience | Academic |
Author | Niu, Yuequn Xia, Dajing Lu, Wei Wu, Han Kong, Jianlu Wu, Yongfeng Sun, Wenjie Li, Hongyi Wu, Yihua Ding, Kefeng Zhang, Honghe Shen, Han-Ming |
Author_xml | – sequence: 1 givenname: Wei surname: Lu fullname: Lu, Wei – sequence: 2 givenname: Honghe surname: Zhang fullname: Zhang, Honghe – sequence: 3 givenname: Yuequn surname: Niu fullname: Niu, Yuequn – sequence: 4 givenname: Yongfeng surname: Wu fullname: Wu, Yongfeng – sequence: 5 givenname: Wenjie surname: Sun fullname: Sun, Wenjie – sequence: 6 givenname: Hongyi surname: Li fullname: Li, Hongyi – sequence: 7 givenname: Jianlu surname: Kong fullname: Kong, Jianlu – sequence: 8 givenname: Kefeng surname: Ding fullname: Ding, Kefeng – sequence: 9 givenname: Han-Ming surname: Shen fullname: Shen, Han-Ming – sequence: 10 givenname: Han surname: Wu fullname: Wu, Han – sequence: 11 givenname: Dajing surname: Xia fullname: Xia, Dajing – sequence: 12 givenname: Yihua surname: Wu fullname: Wu, Yihua |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28697764$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kstq3DAUhk1JaS7tA3RTDN1kUac6ti7WpjCEXgJDC6FdC1mWZxRsaSrZgXmdPmmPZzJtJrQY5IP86ZN--ZxnJz54m2WvgVwB1Px9glLSqiAgCsJrVshn2RlQwQvKZH3yqD7NzlO6IwjWgr7ITsuaSyE4Pct-LYNf5egtTGgdlrdfF3nvvCGEiyqPdjX1erTtDkmD7vvcWBz6CVmjvbEx38TQu85GPbrg3-WDWx1K5-91wirXvs3txo1r2zvd54NN1pv1Fn35GLVPbubzZpunDZ5nPsfgbgtgpGCbl9nzTvfJvnp4X2Q_Pn38fv2lWH77fHO9WBaGcTIWNakA2pIaLRkVDWhMCwCaG1lXotFAdcUkB9YSbS0DzWTZtBxMaU3H66q6yG723jboO7WJbtBxq4J2ajcR4krpODrTWyUa3NIYS4A3tNYgqWloaWswxrSm69D1Ye_aTM1gW2M9xuyPpMdfvFurVbhXjBEqBEPB5YMghp-TTaMaXJpvXnsbpqRAAqbiNSWIvn2C3oUperwqpEpeUklK-ZdaaQzgfBdwXzNL1YIBlELWcqau_kHh09rBGey-zuH80YI3j4P-SXjoMATEHjAxpBRtp4wbd-2BZtcrIGruZbXvZYU_Tc29rGY1PFl5kP9_zW9Qe_Yn |
CitedBy_id | crossref_primary_10_1089_cbr_2019_3294 crossref_primary_10_1007_s13205_020_02443_7 crossref_primary_10_1158_1078_0432_CCR_17_2376 crossref_primary_10_3389_fgene_2023_1222059 crossref_primary_10_1016_j_omtn_2019_06_008 crossref_primary_10_1038_s41598_022_15189_4 crossref_primary_10_5808_GI_2020_18_4_e36 crossref_primary_10_1002_jcb_29559 crossref_primary_10_1016_j_prp_2021_153569 crossref_primary_10_3892_ol_2022_13290 crossref_primary_10_1016_j_heliyon_2024_e37715 crossref_primary_10_1002_mog2_51 crossref_primary_10_1097_MPA_0000000000002136 crossref_primary_10_1016_j_aquaculture_2019_06_015 crossref_primary_10_1093_toxsci_kfy039 crossref_primary_10_1016_j_biopha_2019_109049 crossref_primary_10_1186_s12935_021_01772_8 crossref_primary_10_1177_1073274818803942 crossref_primary_10_3390_cells11152448 crossref_primary_10_1016_j_amjms_2022_12_014 crossref_primary_10_1042_BSR20211175 crossref_primary_10_1002_jgm_3133 crossref_primary_10_1186_s12935_021_02270_7 crossref_primary_10_3390_ncrna8030036 crossref_primary_10_1038_s41598_023_36485_7 crossref_primary_10_1007_s12672_022_00522_0 crossref_primary_10_1002_jcp_29251 crossref_primary_10_18632_aging_204280 crossref_primary_10_32604_oncologie_2022_027545 crossref_primary_10_1007_s11010_020_03896_3 crossref_primary_10_1016_j_bbrc_2019_09_090 crossref_primary_10_1002_cbin_11314 crossref_primary_10_1007_s11010_020_03704_y crossref_primary_10_1021_acs_jafc_3c06104 crossref_primary_10_4103_cjop_CJOP_D_23_00076 crossref_primary_10_1007_s00109_018_1654_5 crossref_primary_10_3390_ijms20112767 crossref_primary_10_1186_s12943_019_1081_4 crossref_primary_10_3892_etm_2023_12102 crossref_primary_10_1038_s41598_021_90538_3 crossref_primary_10_1111_1759_7714_14844 crossref_primary_10_3390_ijms232112737 crossref_primary_10_1038_s41419_019_1811_y crossref_primary_10_1016_j_bbcan_2021_188612 crossref_primary_10_3390_cancers14020439 crossref_primary_10_1080_15476286_2018_1553481 crossref_primary_10_1093_abbs_gmz110 crossref_primary_10_1002_jcb_29542 crossref_primary_10_1097_CAD_0000000000001167 crossref_primary_10_1016_j_lfs_2018_12_024 crossref_primary_10_1016_j_biopha_2018_02_099 crossref_primary_10_1089_hgtb_2019_115 crossref_primary_10_3389_fmolb_2022_923584 crossref_primary_10_1186_s12935_024_03446_7 crossref_primary_10_1186_s12979_021_00258_5 crossref_primary_10_1111_jcmm_14749 crossref_primary_10_18632_aging_205908 crossref_primary_10_2174_1566524023666230329085557 crossref_primary_10_2217_epi_2019_0382 crossref_primary_10_18632_aging_203289 crossref_primary_10_1016_j_prp_2021_153528 crossref_primary_10_1080_21655979_2021_1953210 crossref_primary_10_1093_carcin_bgz125 crossref_primary_10_1016_j_exer_2022_109034 crossref_primary_10_3892_ol_2021_12913 crossref_primary_10_1186_s12935_020_01221_y crossref_primary_10_18632_aging_101656 crossref_primary_10_1007_s43032_022_00955_6 crossref_primary_10_1186_s13046_019_1152_9 crossref_primary_10_1016_j_mtbio_2023_100632 crossref_primary_10_62347_VRBK1334 crossref_primary_10_1186_s12890_020_01240_5 crossref_primary_10_1002_1873_3468_13698 crossref_primary_10_1016_j_omtn_2024_102363 crossref_primary_10_1007_s12094_021_02658_x crossref_primary_10_1093_toxsci_kfy107 crossref_primary_10_1016_j_envres_2023_115942 crossref_primary_10_3389_fonc_2021_761582 crossref_primary_10_2147_IJGM_S321648 crossref_primary_10_1016_j_biopha_2020_110239 crossref_primary_10_1515_chem_2022_0259 crossref_primary_10_1093_toxres_tfab097 crossref_primary_10_1155_2020_4157606 crossref_primary_10_1007_s12010_024_04992_6 crossref_primary_10_1007_s13577_018_0206_1 crossref_primary_10_1080_15384101_2022_2154556 crossref_primary_10_1016_j_yexcr_2020_112007 crossref_primary_10_1007_s12020_019_02030_8 crossref_primary_10_1042_BSR20171667 crossref_primary_10_1186_s12967_019_2068_z crossref_primary_10_1016_j_prp_2022_154018 crossref_primary_10_3389_fgene_2021_682904 crossref_primary_10_1007_s10815_023_02959_w crossref_primary_10_3727_096504018X15202945197589 crossref_primary_10_3389_fgene_2021_694571 crossref_primary_10_3892_etm_2017_5172 crossref_primary_10_1016_j_prp_2020_152823 crossref_primary_10_3389_fmed_2021_761724 crossref_primary_10_1007_s00018_025_05602_2 crossref_primary_10_3390_cells8101162 crossref_primary_10_1042_BSR20200390 crossref_primary_10_1016_j_omto_2019_08_010 crossref_primary_10_3892_ijo_2018_4524 crossref_primary_10_2174_1568009621666210203110305 crossref_primary_10_1002_jcb_27099 crossref_primary_10_1097_MD_0000000000033192 crossref_primary_10_3892_ol_2020_11754 crossref_primary_10_1111_cns_13152 crossref_primary_10_1016_j_biopha_2021_112360 crossref_primary_10_1016_j_biopha_2019_109457 crossref_primary_10_3389_fgene_2022_1069112 crossref_primary_10_3390_cancers12051245 crossref_primary_10_1111_cpr_12406 crossref_primary_10_1111_cas_14509 crossref_primary_10_1186_s12943_017_0716_6 crossref_primary_10_1080_21655979_2021_2012402 crossref_primary_10_1186_s12935_023_03105_3 crossref_primary_10_14712_fb2022068010016 crossref_primary_10_1038_s41419_023_05840_x crossref_primary_10_3390_jpm11060468 crossref_primary_10_1080_21655979_2022_2053802 crossref_primary_10_3389_fonc_2021_761979 crossref_primary_10_1002_jgm_3099 crossref_primary_10_1016_j_gene_2018_12_077 crossref_primary_10_1186_s10020_022_00561_x crossref_primary_10_1016_j_jhazmat_2023_131288 crossref_primary_10_1007_s10620_020_06691_8 crossref_primary_10_2147_COPD_S400985 crossref_primary_10_1038_s41419_019_1948_8 crossref_primary_10_1016_j_celrep_2019_04_101 crossref_primary_10_3389_fonc_2022_911613 crossref_primary_10_1038_s41419_018_0962_6 crossref_primary_10_1007_s11064_021_03311_3 crossref_primary_10_1016_j_prp_2019_01_017 crossref_primary_10_1139_bcb_2019_0065 crossref_primary_10_1111_jcmm_14883 crossref_primary_10_1016_j_bcp_2020_114095 crossref_primary_10_1016_j_lfs_2019_117134 crossref_primary_10_18632_aging_101920 crossref_primary_10_3389_fonc_2021_756148 crossref_primary_10_1002_jcla_22930 crossref_primary_10_1007_s10867_023_09633_3 crossref_primary_10_1007_s00018_020_03691_9 crossref_primary_10_3389_fgene_2022_959456 crossref_primary_10_1186_s13046_020_01819_0 crossref_primary_10_1007_s12011_023_03738_5 crossref_primary_10_1016_j_biopha_2022_112788 crossref_primary_10_1002_jcb_28973 crossref_primary_10_1038_s41419_020_2409_0 crossref_primary_10_1186_s13046_019_1421_7 crossref_primary_10_3233_CBM_230154 crossref_primary_10_1016_j_canlet_2024_217153 crossref_primary_10_1007_s10620_020_06690_9 crossref_primary_10_3389_fimmu_2022_878740 crossref_primary_10_3389_fonc_2020_01546 crossref_primary_10_3892_etm_2020_8518 crossref_primary_10_1016_j_biopha_2019_109495 crossref_primary_10_1016_j_bbrc_2018_09_191 crossref_primary_10_1007_s11060_021_03836_1 crossref_primary_10_1002_jcb_29635 crossref_primary_10_3390_ijms21041193 crossref_primary_10_1002_jcb_26802 crossref_primary_10_1007_s13402_021_00602_3 crossref_primary_10_1016_j_omtn_2019_10_031 crossref_primary_10_1089_cbr_2019_3363 crossref_primary_10_1080_1354750X_2023_2269320 crossref_primary_10_1016_j_cyto_2020_155286 crossref_primary_10_3389_fgene_2020_00929 crossref_primary_10_2147_OTT_S261973 crossref_primary_10_3390_ncrna6030025 crossref_primary_10_1016_j_ijbiomac_2022_02_094 crossref_primary_10_1016_j_biopha_2022_112963 crossref_primary_10_1038_s41598_025_85793_7 crossref_primary_10_1186_s13578_019_0302_2 crossref_primary_10_18632_aging_204426 crossref_primary_10_3389_fgene_2022_889530 crossref_primary_10_1016_j_canlet_2024_217093 crossref_primary_10_1038_s41420_022_01276_y crossref_primary_10_1002_cbin_11270 crossref_primary_10_3892_ol_2021_13173 crossref_primary_10_1007_s12010_022_03855_2 crossref_primary_10_1016_j_prp_2023_155015 crossref_primary_10_1080_08916934_2023_2250099 crossref_primary_10_3390_ijms24021310 crossref_primary_10_26508_lsa_202302408 crossref_primary_10_1007_s10142_024_01403_1 crossref_primary_10_1186_s13046_022_02453_8 crossref_primary_10_1186_s12943_018_0870_5 crossref_primary_10_1038_s41420_021_00407_1 crossref_primary_10_1038_s41419_019_1332_8 crossref_primary_10_3390_pharmaceutics13010009 crossref_primary_10_1073_pnas_1900997116 crossref_primary_10_1038_s41401_021_00655_y crossref_primary_10_1155_2022_2485055 crossref_primary_10_1111_jcmm_18247 crossref_primary_10_3892_ijo_2019_4734 crossref_primary_10_1016_j_bbrc_2017_12_047 crossref_primary_10_3389_fonc_2021_690641 crossref_primary_10_1038_s41388_019_0904_5 crossref_primary_10_1089_cbr_2019_3259 crossref_primary_10_1016_j_toxlet_2019_11_024 crossref_primary_10_1007_s00432_020_03161_6 |
Cites_doi | 10.1007/s13277-015-4073-z 10.1136/jmedgenet-2015-103334 10.1038/nature05874 10.1016/j.ccr.2014.03.010 10.1093/carcin/bgs381 10.1158/0008-5472.CAN-10-4554 10.1016/j.jmb.2013.02.030 10.1074/jbc.M116.750950 10.1038/bjc.2014.383 10.1002/ijc.29210 10.1016/j.cell.2011.07.014 10.18632/oncotarget.5728 10.1016/j.cell.2009.11.007 10.1007/s13277-014-2150-3 10.1002/jso.23648 10.18632/oncotarget.8338 10.1038/cdd.2013.123 10.3322/caac.21332 10.1038/onc.2015.223 10.18632/oncotarget.8063 10.18632/oncotarget.4154 10.1016/j.cell.2009.02.006 10.1002/cbf.3079 10.1016/j.canlet.2015.11.043 10.1097/JTO.0000000000000470 10.1016/j.ccr.2009.03.016 10.3322/caac.21235 10.1097/MPA.0000000000000333 10.1615/CritRevOncog.2014011802 10.5507/bp.2012.049 10.1159/000147748 10.1016/j.cell.2011.09.032 10.1111/cas.12030 10.18632/oncotarget.7292 10.1080/15476286.2015.1063770 10.1158/0008-5472.CAN-14-2931 10.5487/TR.2010.26.4.245 10.1038/nature11233 10.1016/j.cell.2011.09.028 10.1038/sj.bjc.6605530 10.1158/1078-0432.CCR-13-1455 10.1002/stem.1448 10.1038/onc.2015.366 10.18632/oncotarget.12995 10.1097/JTO.0b013e318283d958 10.1080/15384101.2015.1006048 10.1016/j.tig.2011.06.001 10.1016/j.canlet.2016.02.018 10.1016/j.ccell.2016.03.004 10.1093/annonc/mdv318 10.1101/gr.082701.108 10.1158/0008-5472.CAN-14-3721 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2017 BioMed Central Ltd. Copyright BioMed Central 2017 The Author(s). 2017 |
Copyright_xml | – notice: COPYRIGHT 2017 BioMed Central Ltd. – notice: Copyright BioMed Central 2017 – notice: The Author(s). 2017 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s12943-017-0685-9 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1476-4598 |
EndPage | 14 |
ExternalDocumentID | oai_doaj_org_article_7b560cce016b48a194cb42e81cccdcff PMC5504775 A511279899 28697764 10_1186_s12943_017_0685_9 |
Genre | Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation_xml | – fundername: ; grantid: 31471297 – fundername: ; grantid: 81400371; 81302455 |
GroupedDBID | --- 0R~ 123 29M 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HH5 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PZZ RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF FRP NPM PMFND 7TO 7XB 8FK AHSBF AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c560t-80311d24ca9547b1a017111a6c9837ba14a359615d0aee51a592bd61c2ecf6833 |
IEDL.DBID | M48 |
ISSN | 1476-4598 |
IngestDate | Wed Aug 27 01:22:58 EDT 2025 Thu Aug 21 14:12:11 EDT 2025 Fri Jul 11 05:20:49 EDT 2025 Fri Jul 25 20:03:48 EDT 2025 Tue Jun 17 21:49:29 EDT 2025 Tue Jun 10 20:08:39 EDT 2025 Wed Feb 19 02:41:09 EST 2025 Thu Apr 24 23:01:37 EDT 2025 Tue Jul 01 01:01:14 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | linc00673 Epithelial mesenchymal transition miR-150-5p Competing endogenous RNA Non-small cell lung cancer |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c560t-80311d24ca9547b1a017111a6c9837ba14a359615d0aee51a592bd61c2ecf6833 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12943-017-0685-9 |
PMID | 28697764 |
PQID | 1926249029 |
PQPubID | 42702 |
PageCount | 14 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_7b560cce016b48a194cb42e81cccdcff pubmedcentral_primary_oai_pubmedcentral_nih_gov_5504775 proquest_miscellaneous_1918376840 proquest_journals_1926249029 gale_infotracmisc_A511279899 gale_infotracacademiconefile_A511279899 pubmed_primary_28697764 crossref_citationtrail_10_1186_s12943_017_0685_9 crossref_primary_10_1186_s12943_017_0685_9 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-07-11 |
PublicationDateYYYYMMDD | 2017-07-11 |
PublicationDate_xml | – month: 07 year: 2017 text: 2017-07-11 day: 11 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Molecular cancer |
PublicationTitleAlternate | Mol Cancer |
PublicationYear | 2017 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | L Zhang (685_CR50) 2013; 34 L Salmena (685_CR25) 2011; 146 CE DeSantis (685_CR9) 2014; 64 J Ferlay (685_CR10) 2015; 136 M Cesana (685_CR26) 2011; 147 E Rulli (685_CR44) 2015; 26 JH Yuan (685_CR18) 2014; 25 L Qu (685_CR28) 2016; 29 A Barbachano (685_CR38) 2016; 35 D Han (685_CR51) 2016; 7 L Ombrato (685_CR11) 2014; 19 E Birney (685_CR3) 2007; 447 Y Wu (685_CR17) 2009; 15 RL Siegel (685_CR53) 2016; 66 CP Ponting (685_CR8) 2009; 136 Y Wu (685_CR16) 2010; 102 B Santosh (685_CR2) 2015; 33 M Jin (685_CR35) 2014; 9 Q Ji (685_CR34) 2014; 111 T Yokobori (685_CR37) 2013; 104 E Sanchez-Tillo (685_CR40) 2014; 21 P Han (685_CR7) 2015; 12 H Hirata (685_CR32) 2015; 75 W Sun (685_CR43) 2016; 7 X Qi (685_CR52) 2015; 52 P Martin (685_CR47) 2013; 8 Z Luo (685_CR36) 2013; 31 Y Fan (685_CR19) 2014; 20 T Li (685_CR20) 2016; 35 K Yang (685_CR42) 2015; 44 ED Hay (685_CR12) 1995; 154 WC Liang (685_CR30) 2015; 6 D Wang (685_CR33) 2015; 6 M Gachechiladze (685_CR46) 2012; 156 S Djebali (685_CR1) 2012; 489 T Li (685_CR39) 2015; 75 P Zhang (685_CR54) 2015; 14 H Jiang (685_CR48) 2014; 35 AC Tuck (685_CR5) 2011; 27 685_CR24 Q Liu (685_CR23) 2016; 37 IV Novikova (685_CR6) 2013; 425 SP Li (685_CR29) 2016; 7 JM Donahue (685_CR45) 2014; 110 JP Thiery (685_CR13) 2009; 139 X Chen (685_CR21) 2016; 7 M Terashima (685_CR22) 2017; 292 J Tang (685_CR31) 2016; 371 H Yu (685_CR49) 2015; 10 RC Friedman (685_CR4) 2009; 19 MK Asiedu (685_CR15) 2011; 71 FA Karreth (685_CR27) 2011; 147 HX Zhan (685_CR41) 2016; 374 H Son (685_CR14) 2010; 26 26683775 - Cancer Lett. 2016 Feb 28;371(2):301-13 23069884 - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Sep;156(3):200-3 22000016 - Cell. 2011 Oct 14;147(2):382-95 27285757 - Oncotarget. 2016 Jul 5;7(27):42431-42446 24895315 - J Surg Oncol. 2014 Aug;110(2):97-8 24449823 - Clin Cancer Res. 2014 Mar 15;20(6):1531-41 24278531 - Toxicol Res. 2010 Dec;26(4):245-52 26358722 - J Med Genet. 2015 Oct;52(10 ):710-8 25600645 - Cancer Res. 2015 Apr 1;75(7):1322-31 19239885 - Cell. 2009 Feb 20;136(4):629-41 26871477 - Oncotarget. 2016 Mar 8;7(10):11595-608 23765923 - Stem Cells. 2013 Sep;31(9):1749-62 26898939 - Cancer Lett. 2016 May 1;374(2):261-71 25090005 - PLoS One. 2014 Aug 04;9(8):e103965 26068968 - Oncotarget. 2015 Sep 8;6(26):22513-25 26073087 - Oncogene. 2016 Mar 24;35(12 ):1575-84 23467124 - J Mol Biol. 2013 Oct 9;425(19):3731-46 20087353 - Br J Cancer. 2010 Feb 16;102(4):639-44 24890451 - CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71 21555371 - Cancer Res. 2011 Jul 1;71(13):4707-19 23222811 - Carcinogenesis. 2013 Mar;34(3):577-86 8714286 - Acta Anat (Basel). 1995;154(1):8-20 25475931 - Cell Biochem Funct. 2015 Jan;33(1):14-22 26177256 - RNA Biol. 2015;12(10):1094-8 19945376 - Cell. 2009 Nov 25;139(5):871-90 19411070 - Cancer Cell. 2009 May 5;15(5):416-28 25590602 - J Thorac Oncol. 2015 Apr;10(4):645-54 27806322 - Oncotarget. 2016 Dec 20;7(51):84480-84485 27852821 - J Biol Chem. 2017 Jan 6;292(1):82-99 25220842 - Int J Cancer. 2015 Mar 1;136(5):E359-86 26455323 - Oncogene. 2016 Jun 9;35(23):2991-3003 21802130 - Cell. 2011 Aug 5;146(3):353-8 27117758 - Cancer Cell. 2016 May 9;29(5):653-68 25607528 - Cell Cycle. 2015 ;14 (4):481-7 23524403 - J Thorac Oncol. 2013 May;8(5):530-42 27027352 - Oncotarget. 2016 May 3;7(18):25558-75 28851432 - Mol Cancer. 2017 Aug 29;16(1):144 21741109 - Trends Genet. 2011 Oct;27(10):422-32 24013721 - Cell Death Differ. 2014 Feb;21(2):247-57 18955434 - Genome Res. 2009 Jan;19(1):92-105 26742998 - CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 26989025 - Oncotarget. 2016 Apr 19;7(16):22159-73 26209642 - Ann Oncol. 2015 Oct;26(10):2079-84 24768205 - Cancer Cell. 2014 May 12;25(5):666-81 26516927 - Oncotarget. 2015 Dec 1;6(38):41045-55 22000014 - Cell. 2011 Oct 14;147(2):358-69 26069248 - Cancer Res. 2015 Aug 1;75(15):3181-91 23013135 - Cancer Sci. 2013 Jan;104(1):48-54 25522282 - Pancreas. 2015 Apr;44(3):370-9 25404150 - Crit Rev Oncog. 2014;19(5):349-61 26404132 - Tumour Biol. 2016 Feb;37(2):2665-72 24913707 - Tumour Biol. 2014 Aug;35(8):7383-9 17571346 - Nature. 2007 Jun 14;447(7146):799-816 25025966 - Br J Cancer. 2014 Aug 12;111(4):736-48 22955620 - Nature. 2012 Sep 6;489(7414):101-8 |
References_xml | – volume: 37 start-page: 2665 year: 2016 ident: 685_CR23 publication-title: Tumour Biol doi: 10.1007/s13277-015-4073-z – volume: 52 start-page: 710 year: 2015 ident: 685_CR52 publication-title: J Med Genet doi: 10.1136/jmedgenet-2015-103334 – volume: 447 start-page: 799 year: 2007 ident: 685_CR3 publication-title: Nature doi: 10.1038/nature05874 – volume: 25 start-page: 666 year: 2014 ident: 685_CR18 publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.03.010 – volume: 34 start-page: 577 year: 2013 ident: 685_CR50 publication-title: Carcinogenesis doi: 10.1093/carcin/bgs381 – volume: 71 start-page: 4707 year: 2011 ident: 685_CR15 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-4554 – volume: 425 start-page: 3731 year: 2013 ident: 685_CR6 publication-title: J Mol Biol doi: 10.1016/j.jmb.2013.02.030 – volume: 292 start-page: 82 year: 2017 ident: 685_CR22 publication-title: J Biol Chem doi: 10.1074/jbc.M116.750950 – volume: 111 start-page: 736 year: 2014 ident: 685_CR34 publication-title: Br J Cancer doi: 10.1038/bjc.2014.383 – volume: 136 start-page: E359 year: 2015 ident: 685_CR10 publication-title: Int J Cancer doi: 10.1002/ijc.29210 – volume: 146 start-page: 353 year: 2011 ident: 685_CR25 publication-title: Cell doi: 10.1016/j.cell.2011.07.014 – volume: 6 start-page: 41045 year: 2015 ident: 685_CR33 publication-title: Oncotarget doi: 10.18632/oncotarget.5728 – volume: 139 start-page: 871 year: 2009 ident: 685_CR13 publication-title: Cell doi: 10.1016/j.cell.2009.11.007 – volume: 35 start-page: 7383 year: 2014 ident: 685_CR48 publication-title: Tumour Biol doi: 10.1007/s13277-014-2150-3 – volume: 110 start-page: 97 year: 2014 ident: 685_CR45 publication-title: J Surg Oncol doi: 10.1002/jso.23648 – ident: 685_CR24 doi: 10.18632/oncotarget.8338 – volume: 21 start-page: 247 year: 2014 ident: 685_CR40 publication-title: Cell Death Differ doi: 10.1038/cdd.2013.123 – volume: 66 start-page: 7 year: 2016 ident: 685_CR53 publication-title: CA Cancer J Clin doi: 10.3322/caac.21332 – volume: 35 start-page: 1575 year: 2016 ident: 685_CR20 publication-title: Oncogene doi: 10.1038/onc.2015.223 – volume: 7 start-page: 22159 year: 2016 ident: 685_CR51 publication-title: Oncotarget doi: 10.18632/oncotarget.8063 – volume: 6 start-page: 22513 year: 2015 ident: 685_CR30 publication-title: Oncotarget doi: 10.18632/oncotarget.4154 – volume: 136 start-page: 629 year: 2009 ident: 685_CR8 publication-title: Cell doi: 10.1016/j.cell.2009.02.006 – volume: 33 start-page: 14 year: 2015 ident: 685_CR2 publication-title: Cell Biochem Funct doi: 10.1002/cbf.3079 – volume: 371 start-page: 301 year: 2016 ident: 685_CR31 publication-title: Cancer Lett doi: 10.1016/j.canlet.2015.11.043 – volume: 10 start-page: 645 year: 2015 ident: 685_CR49 publication-title: J Thorac Oncol doi: 10.1097/JTO.0000000000000470 – volume: 15 start-page: 416 year: 2009 ident: 685_CR17 publication-title: Cancer Cell doi: 10.1016/j.ccr.2009.03.016 – volume: 64 start-page: 252 year: 2014 ident: 685_CR9 publication-title: CA Cancer J Clin doi: 10.3322/caac.21235 – volume: 44 start-page: 370 year: 2015 ident: 685_CR42 publication-title: Pancreas doi: 10.1097/MPA.0000000000000333 – volume: 7 start-page: 42431 year: 2016 ident: 685_CR29 publication-title: Oncotarget – volume: 19 start-page: 349 year: 2014 ident: 685_CR11 publication-title: Crit Rev Oncog doi: 10.1615/CritRevOncog.2014011802 – volume: 156 start-page: 200 year: 2012 ident: 685_CR46 publication-title: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub doi: 10.5507/bp.2012.049 – volume: 154 start-page: 8 year: 1995 ident: 685_CR12 publication-title: Acta Anat (Basel) doi: 10.1159/000147748 – volume: 147 start-page: 382 year: 2011 ident: 685_CR27 publication-title: Cell doi: 10.1016/j.cell.2011.09.032 – volume: 104 start-page: 48 year: 2013 ident: 685_CR37 publication-title: Cancer Sci doi: 10.1111/cas.12030 – volume: 7 start-page: 11595 year: 2016 ident: 685_CR43 publication-title: Oncotarget doi: 10.18632/oncotarget.7292 – volume: 12 start-page: 1094 year: 2015 ident: 685_CR7 publication-title: RNA Biol doi: 10.1080/15476286.2015.1063770 – volume: 75 start-page: 1322 year: 2015 ident: 685_CR32 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-14-2931 – volume: 26 start-page: 245 year: 2010 ident: 685_CR14 publication-title: Toxicol Res doi: 10.5487/TR.2010.26.4.245 – volume: 489 start-page: 101 year: 2012 ident: 685_CR1 publication-title: Nature doi: 10.1038/nature11233 – volume: 147 start-page: 358 year: 2011 ident: 685_CR26 publication-title: Cell doi: 10.1016/j.cell.2011.09.028 – volume: 102 start-page: 639 year: 2010 ident: 685_CR16 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6605530 – volume: 20 start-page: 1531 year: 2014 ident: 685_CR19 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-1455 – volume: 31 start-page: 1749 year: 2013 ident: 685_CR36 publication-title: Stem Cells doi: 10.1002/stem.1448 – volume: 35 start-page: 2991 year: 2016 ident: 685_CR38 publication-title: Oncogene doi: 10.1038/onc.2015.366 – volume: 7 start-page: 84480 year: 2016 ident: 685_CR21 publication-title: Oncotarget doi: 10.18632/oncotarget.12995 – volume: 8 start-page: 530 year: 2013 ident: 685_CR47 publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e318283d958 – volume: 14 start-page: 481 year: 2015 ident: 685_CR54 publication-title: Cell Cycle doi: 10.1080/15384101.2015.1006048 – volume: 27 start-page: 422 year: 2011 ident: 685_CR5 publication-title: Trends Genet doi: 10.1016/j.tig.2011.06.001 – volume: 374 start-page: 261 year: 2016 ident: 685_CR41 publication-title: Cancer Lett doi: 10.1016/j.canlet.2016.02.018 – volume: 29 start-page: 653 year: 2016 ident: 685_CR28 publication-title: Cancer Cell doi: 10.1016/j.ccell.2016.03.004 – volume: 26 start-page: 2079 year: 2015 ident: 685_CR44 publication-title: Ann Oncol doi: 10.1093/annonc/mdv318 – volume: 9 year: 2014 ident: 685_CR35 publication-title: PLoS One – volume: 19 start-page: 92 year: 2009 ident: 685_CR4 publication-title: Genome Res doi: 10.1101/gr.082701.108 – volume: 75 start-page: 3181 year: 2015 ident: 685_CR39 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-14-3721 – reference: 26209642 - Ann Oncol. 2015 Oct;26(10):2079-84 – reference: 25600645 - Cancer Res. 2015 Apr 1;75(7):1322-31 – reference: 25522282 - Pancreas. 2015 Apr;44(3):370-9 – reference: 27852821 - J Biol Chem. 2017 Jan 6;292(1):82-99 – reference: 25404150 - Crit Rev Oncog. 2014;19(5):349-61 – reference: 24890451 - CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71 – reference: 24895315 - J Surg Oncol. 2014 Aug;110(2):97-8 – reference: 21802130 - Cell. 2011 Aug 5;146(3):353-8 – reference: 20087353 - Br J Cancer. 2010 Feb 16;102(4):639-44 – reference: 27285757 - Oncotarget. 2016 Jul 5;7(27):42431-42446 – reference: 21741109 - Trends Genet. 2011 Oct;27(10):422-32 – reference: 22955620 - Nature. 2012 Sep 6;489(7414):101-8 – reference: 25607528 - Cell Cycle. 2015 ;14 (4):481-7 – reference: 24768205 - Cancer Cell. 2014 May 12;25(5):666-81 – reference: 19239885 - Cell. 2009 Feb 20;136(4):629-41 – reference: 25025966 - Br J Cancer. 2014 Aug 12;111(4):736-48 – reference: 26068968 - Oncotarget. 2015 Sep 8;6(26):22513-25 – reference: 26069248 - Cancer Res. 2015 Aug 1;75(15):3181-91 – reference: 22000014 - Cell. 2011 Oct 14;147(2):358-69 – reference: 23467124 - J Mol Biol. 2013 Oct 9;425(19):3731-46 – reference: 22000016 - Cell. 2011 Oct 14;147(2):382-95 – reference: 28851432 - Mol Cancer. 2017 Aug 29;16(1):144 – reference: 27117758 - Cancer Cell. 2016 May 9;29(5):653-68 – reference: 25090005 - PLoS One. 2014 Aug 04;9(8):e103965 – reference: 19411070 - Cancer Cell. 2009 May 5;15(5):416-28 – reference: 23013135 - Cancer Sci. 2013 Jan;104(1):48-54 – reference: 23069884 - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Sep;156(3):200-3 – reference: 18955434 - Genome Res. 2009 Jan;19(1):92-105 – reference: 24278531 - Toxicol Res. 2010 Dec;26(4):245-52 – reference: 26455323 - Oncogene. 2016 Jun 9;35(23):2991-3003 – reference: 19945376 - Cell. 2009 Nov 25;139(5):871-90 – reference: 24013721 - Cell Death Differ. 2014 Feb;21(2):247-57 – reference: 26898939 - Cancer Lett. 2016 May 1;374(2):261-71 – reference: 23765923 - Stem Cells. 2013 Sep;31(9):1749-62 – reference: 26871477 - Oncotarget. 2016 Mar 8;7(10):11595-608 – reference: 26742998 - CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 – reference: 25475931 - Cell Biochem Funct. 2015 Jan;33(1):14-22 – reference: 27027352 - Oncotarget. 2016 May 3;7(18):25558-75 – reference: 21555371 - Cancer Res. 2011 Jul 1;71(13):4707-19 – reference: 26404132 - Tumour Biol. 2016 Feb;37(2):2665-72 – reference: 26073087 - Oncogene. 2016 Mar 24;35(12 ):1575-84 – reference: 26989025 - Oncotarget. 2016 Apr 19;7(16):22159-73 – reference: 26177256 - RNA Biol. 2015;12(10):1094-8 – reference: 24449823 - Clin Cancer Res. 2014 Mar 15;20(6):1531-41 – reference: 25590602 - J Thorac Oncol. 2015 Apr;10(4):645-54 – reference: 17571346 - Nature. 2007 Jun 14;447(7146):799-816 – reference: 26516927 - Oncotarget. 2015 Dec 1;6(38):41045-55 – reference: 8714286 - Acta Anat (Basel). 1995;154(1):8-20 – reference: 26358722 - J Med Genet. 2015 Oct;52(10 ):710-8 – reference: 24913707 - Tumour Biol. 2014 Aug;35(8):7383-9 – reference: 27806322 - Oncotarget. 2016 Dec 20;7(51):84480-84485 – reference: 23222811 - Carcinogenesis. 2013 Mar;34(3):577-86 – reference: 26683775 - Cancer Lett. 2016 Feb 28;371(2):301-13 – reference: 25220842 - Int J Cancer. 2015 Mar 1;136(5):E359-86 – reference: 23524403 - J Thorac Oncol. 2013 May;8(5):530-42 |
SSID | ssj0017874 |
Score | 2.6016502 |
Snippet | The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673... Background The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC),... Abstract Background The function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 118 |
SubjectTerms | Adenocarcinoma Apoptosis - genetics Base Sequence Bioinformatics Biomarkers Cancer therapies Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Cell cycle Cell growth Cell Line, Tumor Cell migration Cell Movement - genetics Cell proliferation Cell Proliferation - genetics Cell Survival - genetics Cholecystokinin Colorectal cancer Competing endogenous RNA Deoxyribonucleic acid Development and progression DNA Epigenetics Epithelial mesenchymal transition Epithelial-Mesenchymal Transition - genetics Esophagus Gene Expression Regulation, Neoplastic Genetic aspects Humans Immunofluorescence linc00673 Liver cancer Lung cancer Lung cancer, Non-small cell Lung Neoplasms - genetics Lung Neoplasms - pathology Malignancy Medical prognosis Mesenchyme Metastasis MicroRNA MicroRNAs - genetics MicroRNAs - metabolism miR-150-5p miRNA Models, Biological Neoplasm Invasiveness Non-coding RNA Non-small cell lung cancer Non-small cell lung carcinoma Pancreas Pancreatic cancer Physiological aspects Polymerase chain reaction Prognosis RNA, Long Noncoding - genetics RNA, Long Noncoding - metabolism Studies Survival Analysis Transforming growth factors Tumorigenesis Zinc Finger E-box-Binding Homeobox 1 - genetics Zinc Finger E-box-Binding Homeobox 1 - metabolism |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9swEBejsLGXsXVfXruhwWAwZmrJkmw_ZmOljLUPZYW-CekstwHHCUk6yL-zv7R3shNiBtvLXoKJJKOPn-53Z53uGPvQNFlAkZelTuGPqmWdIgmHtDFQi8Zo4WPOyPMLc3alvl_r671UX-QT1ocH7ifupPDIyQABVROvSoc2N3glQykAoIamIemLnLc1pobzA4ShGs4wRWlOVshqivyGyNWr1Gk1YqEYrP9PkbzHSWN_yT0COn3KngyaI5_0PX7GHoTukD3sc0luDtmj8-GU_Dn7_WPe3XC061OYEzXxy4sJR3USYr4YvuzTz4c6VlnNXNty-n7PW9z4HAgGS76gbD5N6PHxmc-mN9vHaffL0Sc27rqahwXd6WgRxHxG95jgdoPv42tiwOgMxv2Gkxcu5ULCt1ymqBqmevGCXZ1--_n1LB1yMaSA879GIsuFqKUCV2lVeOEozo4QzkCFJq53QrlcV6ge1ZkLQQunK-lrI0AGaEyZ5y_ZAQ4qvGa80T433sk6M0EFMB4KiUqbdE2lXTBVwrLt2lgYApVTvozWRoOlNLZfTotdsLScFpt82jVZ9FE6_lb5Cy34riIF2I5_IOzsADv7L9gl7CPBxZIYwM6BG24z4BApoJadkCJbVGjNJux4VBO3L4yLt4Czg_hYWUFRHFWVSSx-vyumluQS14X5HdVBaUzHqFnCXvX43A1Jlgb1eqMSVoyQOxrzuKSb3sbg4mixqqLQb_7HJB2xxzLuuSIV4pgdrJd34S3qcGv_Lm7Xe9jGRUw priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1di9QwMOiJ4ovo-VU9JYIgiOWabpo2T7KKxyHePRwe7FtIJuneQre77u4J-3f8pc6k3fWKcC-lNJOSYb6TyQxj7-s6C6jystRKfEif-xSNcEhrBV7UqhAu9ow8O1enl_L7pJj0G27rPq1ypxOjovYLoD3yY0GF7aTOcv15-SulrlF0utq30LjL7lHpMuLqcrIPuAQyo-xPMkWljtdo2yRlD1HCV1WkemCLYsn-_xXzDcs0zJq8YYZOHrNHvf_Ixx3Bn7A7oT1k97uOkttD9uCsPyt_yv78WLRTjtF9CgsyUPzifMzRqYTYNYavuib0wUeQ9dw2DaddfN6g-HMgZljxJfX0qUPHJZ_4fDbdvc7a35Y22rhtPQ9LutnRICvzOd1mgqst_o9vyA7GlDDutpxycakjEv7lIkUHMS2Wz9jlybefX0_TviNDCugZbdCcjYTwuQSrC1k6YanajhBWgcZA11kh7ajQ6CT5zIZQCFvo3HklIA9Qq2o0es4OEKnwkvG6cCPlbO4zFWQA5aDM0XXLba0LG5ROWLajjYG-XDl1zWhMDFsqZTpyGlyCIXIanPJxP2XZ1eq4DfgLEXwPSGW244fFamp6qTWlQ7QBAvrFTlZWaAlO5qESAOChrhP2gdjFkDLAxYHt7zQgilRWy4zJnS01xrQJOxpAohDDcHjHcKZXImvzj-UT9m4_TDMpMa4Ni2uCQZ1Mh6lZwl50_LlHKa8UevdKJqwccO4A5-FIO7uKJcYxbpVlWby6fVmv2cM8SlOZCnHEDjar6_AGfbSNexsF8S9KKDtQ priority: 102 providerName: ProQuest |
Title | Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28697764 https://www.proquest.com/docview/1926249029 https://www.proquest.com/docview/1918376840 https://pubmed.ncbi.nlm.nih.gov/PMC5504775 https://doaj.org/article/7b560cce016b48a194cb42e81cccdcff |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dixMxEA_3geKL6PlVPUsEQRDX22zzsfsg0pM7DrFFioV7C0k22ytst7Xtif13_EudyW7rLR6CL2VpJmGzmcnMZCbzI-R1UcQetrw4Mhx-eJ7kEShhHxXS5ayQgtmAGTkYyosx_3wpLvfIFt6q-YCrW107xJMaL8v3P79vPoLAfwgCn8qTFegsjllBmMiViijbJ4egmBQCGgz4n6AC8GYIMnMlIy6ytAly3jpES02Fav5_79k3lFY7ofKGhjp_QO43piXt17zwkOz56ojcqcEmN0fk7qAJoz8iv77MqwkFxz9yc9RddDTsU7A3XQCUocsan97ngWQ1M2VJ8YCflrAzUId8sqQLhPspfM1A7-hsOtk-TqsfBs_gqKly6hd46aMELqczvOjkrjYwHl2jigzZYtRuKKbpIlgSjDKKwHaMxOIxGZ-ffft0ETVgDZEDo2kNmq7HWJ5wZzLBlWUGC_EwZqTLwAe2hnHTExnYT3lsvBfMiCyxuWQu8a6Qaa_3hBzApPwzQgthe9KaJI-l595J61QCVl1iikwYL7MOibdro11TyRwBNUodPJpU6no5NbyCxuXU0OXtrsuiLuPxL-JTXPAdIVbgDn_MlxPdCLRWFqbtnAeT2fLUsIw7yxOfMudc7oqiQ94gu2jkXHg5Z5rrDjBFrLil-2jpqgzc3Q45blGCfLt285bh9FY8NMMyjzyLE2h-tWvGnpgzV_n5NdLAdo1x1rhDntb8uZtSkkow_CXvENXi3Nac2y3V9CpUHweXlislnv_PF31B7iVBtlTE2DE5WC-v_Usw5ta2S_bVpeqSw9Oz4ddRNxyJdIPY_gZnzUdO |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamIS4vCMYtMMBIICREtNh1nOQBoXKZOtb2YdqkvhnbcbpKbRLaDtS_ww_gN3JOLmUR0t72UkW1E9k6x-c7xz4-HyGvsyxwYPICXwv4ESlPfQBh52fSpiyTITMVZ-RoLAdn4tsknOyQP-1dGEyrbG1iZajTwuIe-QHDwnYiCXjysfzhI2sUnq62FBq1Why7zS8I2VYfjr6AfN9wfvj19PPAb1gFfAvovgaT3GMs5cLqJBSRYRorxjCmpU0gWDOaCd0LEwD6NNDOhUyHCTepZJY7m8kYN0DB5N8A4A0w2Ism2wCPgfKL5uSUxfJgBVgqMFsJE8zi0E862FdRBPwPBJeQsJuleQn2Du-Ru42_Svu1gt0nOy7fIzdrBsvNHrk1as7mH5DfwyKf0rzIfVsgINKTcZ-CE2srlhq6rEnvXVp1WS30fE7x1IDOwdxQi8q3pCVyCGWu1sr3dDGbto-z_KfGjT2q85S6Em-SzGHp0AXenrLnG_geXSPuVilo1Gwo5v4iAxN85cQHh9QPy4fk7Fpk9YjswqTcE0Kz0PSk0TwNpBPOSmMjDq4i11kSaicTjwStbJRtyqMjS8dcVWFSLFUtTgVDUChOBa-8275S1rVBrur8CQW-7Yhlvas_iuVUNVZCRQamba0DP9yIWLNEWCO4i5m1NrVZ5pG3qC4KjQ8MzurmDgVMEct4qT66z1ECMbRH9js9wWjYbnOrcKoxWiv1b4l55NW2Gd_ERLzcFRfYBzAAD28Djzyu9XM7JR5LiCak8EjU0dzOnLst-ey8KmkOcbKIovDp1cN6SW4PTkdDNTwaHz8jd3i1siKfsX2yu15euOfgH67Ni2pRUvL9uq3AX1qudo0 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long+non-coding+RNA+linc00673+regulated+non-small+cell+lung+cancer+proliferation%2C+migration%2C+invasion+and+epithelial+mesenchymal+transition+by+sponging+miR-150-5p&rft.jtitle=Molecular+cancer&rft.au=Lu%2C+Wei&rft.au=Zhang%2C+Honghe&rft.au=Niu%2C+Yuequn&rft.au=Wu%2C+Yongfeng&rft.date=2017-07-11&rft.issn=1476-4598&rft.eissn=1476-4598&rft.volume=16&rft.issue=1&rft_id=info:doi/10.1186%2Fs12943-017-0685-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12943_017_0685_9 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon |